ライフサイエンスコーパス: Wellcome Trust

1 Medical Research Council and the Wellcome Trust.

2 n Greater Mekong Sub-region cluster, and the Wellcome Trust.

3 UK Department of Health and Wellcome Trust.

4 search Cambridge Biomedical Research Centre; Wellcome Trust.

5 sconsin Network for Health Research, and the Wellcome Trust.

6 from the Research Councils UK (RCUK) and the Wellcome Trust.

7 epartment for International Development, and Wellcome Trust.

8 y Program "NeuroRehab" University of Zurich, Wellcome Trust.

9 ses, EU 7th framework program PREDEMICS. and Wellcome Trust.

10 UK Medical Research Council and Wellcome Trust.

11 US National Institutes of Health and Wellcome Trust.

12 sion, Medical Research Council (UK), and the Wellcome Trust.

13 UK Department for International Development, Wellcome Trust.

14 ealth, Pan American Health Organization, and Wellcome Trust.

15 Council for Prevention of Blindness and the Wellcome Trust.

16 European Union Seventh Framework Programme, Wellcome Trust.

17 utes of Health, UK Medical Research Council, Wellcome Trust.

18 tion, Partnership for Child Development, and Wellcome Trust.

19 ), the European Union's HRES grants, and the Wellcome Trust.

20 epartment for International Development, and Wellcome Trust.

21 National Institute for Health Research, and Wellcome Trust.

22 alth Research, British Heart Foundation, and Wellcome Trust.

23 European Commission and the Wellcome Trust.

24 Wellcome Trust, Addenbrooke's Charitable Trust, Raymond

25 Wellcome Trust, Ammalife, and National Institute for Hea

26 Wellcome Trust and Bill & Melinda Gates Foundation.

27 Wellcome Trust and Bill & Melinda Gates Foundation.

28 Wellcome Trust and Li Ka Shing Foundation.

29 The Wellcome Trust and Oxford Radcliffe Hospitals Biomedical

30 The Wellcome Trust and the Bill & Melinda Gates Foundation t

31 Wellcome Trust and the Bill & Melinda Gates Foundation.

32 The Wellcome Trust and The Bill & Melinda Gates Foundation.

33 Wellcome Trust and the Bill & Melinda Gates Foundation.

34 h to clinical trials, in November, 2014, the Wellcome Trust and the Center for Infectious Disease Res

35 st 10 000 cases (a collaboration between the Wellcome Trust and the international MS Genetics Consort

36 , a parallel funding partnership between the Wellcome Trust and the UK Department of Health.

37 l Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation (WOM

38 The Bill & Melinda Gates Foundation, the Wellcome Trust, and Medecins Sans Fronteres.

39 National Institute for Health Research, Wellcome Trust, and Medical Research Council.

40 02), Aeras, Bill & Melinda Gates Foundation, Wellcome Trust, and Oxford-Emergent Tuberculosis Consort

41 Bill & Melinda Gates Foundation, Wellcome Trust, and UK Department for International Deve

42 UK Medical Research Council, Wellcome Trust, and University of Bristol.

43 ous Diseases, National Institutes of Health, Wellcome Trust, Bill & Melinda Gates Foundation, Medical

44 UK Medical Research Council, Wellcome Trust, Biotechnology and Biological Sciences Re

45 We applied our method to the Wellcome Trust bipolar disorder data and found a signifi

46 e for Health Research, Department of Health, Wellcome Trust, British Colombia Centre for Disease Cont

47 e, the present standard of care) at the NIHR/Wellcome Trust Cambridge Clinical Research Facility (Cam

48 cine Centre, Else Kroner Fresenius Stiftung, Wellcome Trust, Cancer Research UK, AstraZeneca UK, Univ

49 LUP to genome-wide association data from the Wellcome Trust Case Control Consortium (seven diseases),

50 using Affymetrix SNP genotype data from the Wellcome Trust Case Control Consortium (WTCCC) and uncov

51 od to seven case-control phenotypes from the Wellcome Trust Case Control Consortium (WTCCC) data and

52 from limited published associations from the Wellcome Trust Case Control Consortium (WTCCC) dataset.

53 nic basis of seven common diseases using the Wellcome Trust Case Control Consortium (WTCCC) GWAS resu

54 In a concurrent study, the Wellcome Trust Case Control Consortium (WTCCC) has repor

55 The Wellcome Trust Case Control Consortium (WTCCC) identifie

56 In 2007, the Wellcome Trust Case Control Consortium (WTCCC) performed

57 The Wellcome Trust Case Control Consortium (WTCCC) primary g

58 sociated with coronary artery disease in the Wellcome Trust Case Control Consortium (WTCCC) study (wh

59 riant RA association signals observed in the Wellcome Trust Case Control Consortium (WTCCC) study and

60 We have validated our method in the Wellcome Trust Case Control Consortium (WTCCC) study of

61 hesis, we applied linear mixed models to the Wellcome Trust Case Control Consortium (WTCCC) T2D data

62 ssociation with type 2 diabetes (T2D) in the Wellcome Trust Case Control Consortium (WTCCC) T2D GWAS.

63 predictive model for the KCNJ11 gene to the Wellcome Trust Case Control Consortium (WTCCC) Type 2 di

64 idual level genotype data generated from the Wellcome Trust Case Control Consortium (WTCCC) type 2 di

65 g genetic data from 4,500 individuals in the Wellcome Trust Case Control Consortium (WTCCC), case-con

66 ith CAD risk polymorphisms identified by the Wellcome Trust Case Control Consortium (WTCCC).

67 /C5 loci with RA using imputed data from the Wellcome Trust Case Control Consortium (WTCCC).

68 5619 unscreened controls from phase 2 of the Wellcome Trust Case Control Consortium (WTCCC2).

69 kb), rare copy-number variants (CNVs) in the Wellcome Trust Case Control Consortium 2 (WTCCC2) schizo

70 orks, and we tested it on data sets from the Wellcome Trust Case Control Consortium 2 (WTCCC2), the G

71 re than 5,000 Kenyan children as part of the Wellcome Trust Case Control Consortium 2 (WTCCC2).

72 netics, Archiving and Monograph (MORGAM) and Wellcome Trust Case Control Consortium 2 collections.

73 In a Wellcome Trust Case Control Consortium 2 multiple sclero

74 case-control Parkinson's disease studies (UK Wellcome Trust Case Control Consortium 2, Dutch Parkinso

75 ollected from the BMES cohort as part of the Wellcome Trust Case Control Consortium 2.

76 5,163 UK population controls as part of the Wellcome Trust Case Control Consortium 3 (WTCCC3).

77 the Genetic Consortium for AN (GCAN) and the Wellcome Trust Case Control Consortium 3 (WTCCC3).

78 nd 6015 control individuals (provided by the Wellcome Trust Case Control Consortium and KORA-gen) for

79 ndylitis (AS) was recently identified by the Wellcome Trust Case Control Consortium and the Australo-

80 ply our method to the seven studies from the Wellcome Trust Case Control Consortium and the major dep

81 ent Program for Bipolar Disorder cohort, the Wellcome Trust Case Control Consortium bipolar cohort, a

82 In the Wellcome Trust Case Control Consortium bipolar disorder

83 tion of our framework to the analysis of the Wellcome Trust Case Control Consortium data.

84 n in individuals with Crohn's disease by the Wellcome Trust Case Control Consortium detected strong a

85 lable Affymetrix 500K genotype data from the Wellcome Trust Case Control Consortium for 1,868 BP case

86 iation (GWA) studies were available from the Wellcome Trust Case Control Consortium for 566 anti-TNF-

87 Using SNP data from the Wellcome Trust Case Control Consortium genome-wide assoc

88 We reanalyzed data from the Wellcome Trust Case Control Consortium genome-wide assoc

89 in the case-control samples genotyped by the Wellcome Trust Case Control Consortium study and imputed

90 ion studies based on the HapMap data and the Wellcome Trust Case Control Consortium to demonstrate th

91 We employed genome-wide data from the Wellcome Trust Case Control Consortium to test this hypo

92 tation in 3,004 additional controls from the Wellcome Trust Case Control Consortium was also performe

93 On the benchmark disease, datasets from The Wellcome Trust Case Control Consortium, RAPID ran in abo

94 nd 2938 population controls generated by the Wellcome Trust Case Control Consortium, we set out to de

95 t and National Blood Service cohort from the Wellcome Trust Case Control Consortium.

96 three autoimmune diseases from the original Wellcome Trust Case Control Consortium.

97 d on the first seven diseases studied by the Wellcome Trust Case Control Consortium.

98 th Cohort and seven common diseases from the Wellcome Trust Case Control Consortium.

99 and two shared control sets provided by the Wellcome Trust Case Control Consortium.

100 controls in the UK who were genotyped by the Wellcome Trust Case Control Consortium.

101 were accessed from the data generated by the Wellcome Trust Case Control Consortium.

102 nsively on three data sets obtained from the Wellcome Trust Case Control Consortium: type two diabete

103 ion for rare, recent variants in the outbred Wellcome Trust Case-Control Consortium (WTCCC) data.

104 es of the GWASelect are illustrated with the Wellcome Trust Case-Control Consortium (WTCCC) data.

105 y a powerful genetic mapping approach to the Wellcome Trust Case-Control Consortium and the National

106 The method was applied to the Wellcome Trust Case-Control Consortium Crohn disease (CD

107 An illustration involving the Wellcome Trust Case-Control Consortium data shows severa

108 in five novel loci also had P < 0.05 in the Wellcome Trust Case-Control Consortium dataset and were

109 consistency of this result with one from the Wellcome Trust Case-Control Consortium encourages furthe

110 Finally, SLINGER application on seven Wellcome Trust Case-Control Consortium genome-wide assoc

111 itish Birth Cohort and were genotyped by the Wellcome Trust Case-Control Consortium with the Illumina

112 by the whole-genome association study of the Wellcome Trust Case-Control Consortium, a parallel indep

113 e type 1 diabetes GWAS data collected by the Wellcome Trust Case-Control Consortium.

114 the University of Minnesota established the Wellcome Trust-CIDRAP Ebola Vaccine Team B initiative.

115 The Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW) has rou

116 The Malawi-Liverpool-Wellcome Trust Clinical Research Programme has done sent

117 Wellcome Trust Clinical Research Training Fellowship.

118 A report on the Wellcome Trust Conference on Computational RNA Biology,

119 tended OJIA (eOJIA) patients], and controls (Wellcome Trust control cohort, WTCCC2).

120 ociation analysis with improved power on the Wellcome Trust data consisting of seven common phenotype

121 On Wellcome Trust data for 15,000 individuals, FaST-LMM ran

122 Sciences, Health Foundation, EU, ERC, NIHR, Wellcome Trust, Dutch Cancer Society, Dutch Digestive Fo

123 Medical Research Council, Wellcome Trust, Economic and Social Research Council, an

124 ancer Research, UK Medical Research Council, Wellcome Trust, EU Framework Cancer Pathways.

125 Saudi Arabian Ministry of Health, Wellcome Trust, European Community, and National Institu

126 Gavi, the Vaccine Alliance, Wellcome Trust, European Society for Paediatric Infectio

127 Wellcome Trust, European Union, Medical Research Council

128 A report of the Wellcome Trust Functional Genomics and Systems Biology C

129 Disease (MND) Association, together with The Wellcome Trust, funded the creation of a national DNA Ba

130 Arthritis Research UK, Wellcome Trust, George Koukis Foundation, European Commu

131 d Infectious Diseases, Grant R01AI051355 and Wellcome Trust, Grant 078332.

132 Ka Shing Oxford Global Health Programme and Wellcome Trust, Harvard Center for Communicable Disease

133 Wellcome Trust, Health Metrics Network (WHO).

134 Translational Infection Research Initiative, Wellcome Trust, Health Protection Agency, and the Nation

135 Common Diseases meeting co-sponsored by the Wellcome Trust, held at the Wellcome Trust Hinxton Confe

136 MRC, DfID, Wellcome Trust, Hewlett Foundation.

137 sponsored by the Wellcome Trust, held at the Wellcome Trust Hinxton Conference Centre July 7-10, 2007

138 The MRC-Wellcome Trust Human Developmental Biology Resource (HDB

139 Two meetings, one sponsored by the Wellcome Trust in 2012 and the other by the Global Virol

140 HB was supported by a Wellcome Trust Institutional Strategic Support Fund (via

141 Society for Endocrinology, Wellcome Trust Institutional Strategic Support Fund.

142 for Preventive Medicine (to R.C. May), and a Wellcome Trust Intermediate fellowship (089966, to T. Bi

143 Wellcome Trust Intermediate Fellowship to SRI, Fulbright

144 Wellcome Trust-Mahidol University-Oxford Tropical Medici

145 Department of Health of South Africa, the Wellcome Trust, Medecins Sans Frontieres, European and D

146 Wellcome Trust, Medical Research Council UK, Department

147 Wellcome Trust, Medical Research Council, and National I

148 Wellcome Trust, Medical Research Council, and UK Nationa

149 Wellcome Trust, Medical Research Council, Economic and S

150 Wellcome Trust, MRC, BHF, CR-UK, Kadoorie Charitable Fou

151 Wellcome Trust, National Institute for Health Research S

152 Wellcome Trust, National Institute for Health Research,

153 Medical Research Council, Wellcome Trust, National Institute for Health Research,

154 Wellcome Trust, National Institute for Health Research,

155 Wellcome Trust, National Institute for Health Research,

156 Wellcome Trust, National Institute for Health Research.

157 Wellcome Trust, National Institute for Health Service Su

158 Wellcome Trust, National Institute of Health Research, a

159 Wellcome Trust, National Institute of Health Research, M

160 Wellcome Trust, NIHR Cambridge Biomedical Research Centr

161 Wellcome Trust, NIHR Cambridge Biomedical Research Centr

162 The establishment by the Wellcome Trust of two four-year PhD programmes in neuros

163 Wellcome Trust, Oxford University Hospitals Research Ser

164 The Wellcome Trust, Papworth Hospital, NIHR Cambridge Biomed

165 UK Medical Research Council, UK Wellcome Trust, Parkinson's UK, Patrick Berthoud Trust,

166 Leading funding sources were the Wellcome Trust ( pound688 million, 26.4%) and the Medica

167 Meningitis Research Foundation, Wellcome Trust, Public Health England, European Union.

168 bridge and UCLH Biomedical Research Centres, Wellcome Trust, Raymond and Beverly Sackler Foundation,

169 tion Society (fellowship to T. Bicanic), the Wellcome Trust (research training fellowships WT069991,

170 In the Wellcome Trust Rheumatoid Arthritis study, STAMS-identif

171 Wellcome Trust, Sackler Fund, National Instititute for H

172 rated by the Pathogen Sequencing Unit at the Wellcome Trust Sanger Institute and other collaborating

173 he C. briggsae sequence was generated at The Wellcome Trust Sanger Institute and the Genome Sequencin

174 of the collaboration, who are from NCBI, the Wellcome Trust Sanger Institute and the University of Ca

175 uencing Center, and has been provided to the Wellcome Trust Sanger Institute and the Whitehead Instit

176 Here we describe the Wellcome Trust Sanger Institute Genome Editing database

177 tion between University of Edinburgh and the Wellcome Trust Sanger Institute in the UK and the Genome

178 rate (FDR) of the cleanest dataset from the Wellcome Trust Sanger Institute is 12.5%.

179 The Wellcome Trust Sanger Institute is one of the world's la

180 roughput mouse phenotyping data set from the Wellcome Trust Sanger Institute Mouse Genetics Project,

181 tly being generated as part of the Edinburgh-Wellcome Trust Sanger Institute parasitic nematode EST p

182 wnload (for MacOSX, UNIX and Windows) at the Wellcome Trust Sanger Institute web sites: http://www.sa

183 wnload (for MacOSX, UNIX and Windows) at the Wellcome Trust Sanger Institute web sites: http://www.sa

184 wnload (for MacOSX, UNIX and Windows) at the Wellcome Trust Sanger Institute websites: http://www.san

185 in SPRET/Ei from the Mouse Genomes Project (Wellcome Trust Sanger Institute) and processed these dat

186 erated by the Pathogen Genomics group at the Wellcome Trust Sanger Institute.

187 SMIC), a large-scale database curated by the Wellcome Trust Sanger Institute.

188 zebrafish genomic sequences produced at the Wellcome Trust Sanger Institute.

189 In 1996, as an innovation for the UK, the Wellcome Trust set up two 'American style' four-year PhD

190 Wellcome Trust, Swedish Research Council, and Swedish Re

191 Wellcome Trust, Swedish Research Council, and the Swedis

192 Wellcome Trust, the Bill & Melinda Gates Foundation, and

193 ealth, the CIHR (Canada), the NIHR (UK), the Wellcome Trust, the Henry Smith Charity, and Action Medi

194 Wellcome Trust, the National Institute of Health Researc

195 sical Sciences Research Council (EPSRC), The Wellcome Trust, the National Institute of Health Researc

196 r Health Research, Medical Research Council, Wellcome Trust, The Scottish Government (RESAS).

197 The Wellcome Trust, the Swedish Prison and Probation Service

198 Wellcome Trust, the Swedish Prison and Probation Service

199 Wellcome Trust, the Swedish Research Council, and the Sw

200 WHO, UK Wellcome Trust, the UK Government through the Department

201 Wellcome Trust, the World Bank through the Partnership f

202 Wellcome Trust through the Scottish Translational and Th

203 uropean Union's Seventh Framework Programme, Wellcome Trust Translational Medicine & Therapeutics Pro

204 higher with STAMS than EW_dmGWAS run on the Wellcome Trust Type 1 Diabetes data.

205 of the GlaxoSmithKline group of companies), Wellcome Trust UK, Medical Research Council: Respiratory

206 Wellcome Trust (UK), Medical Research Council of South A

207 rch, National Institute for Health Research, Wellcome Trust (UK), Swedish Association of Local Author

208 WHO, with support from the Wellcome Trust (UK); Medecins Sans Frontieres; the Norwe

209 Wellcome Trust, UK Medical Research Council (MRC), Austr

210 Wellcome Trust, UK Medical Research Council, Dunhill Med

211 Wellcome Trust, UK Medical Research Council, European Un

212 Wellcome Trust, UK Medical Research Council, Li Ka Shing

213 ncil, Aarhus University Research Foundation, Wellcome Trust, UK Medical Research Council, UK NIHR Hea

214 Wellcome Trust, UK National Institute for Health Researc

215 Wellcome Trust, UK National Institute for Health Researc

216 Wellcome Trust, UK, and Global Antibiotic Resistance Par

217 ters for Disease Control and Prevention; and Wellcome Trust, UK.

218 ion Research; Baily Thomas Charitable Trust; Wellcome Trust; UK Medical Research Council; European Un

219 Wellcome Trust via an Edinburgh Clinical Academic Traini

220 from the UK Medical Research Council and the Wellcome Trust, with support from the Economic and Socia

221 from the UK Medical Research Council and the Wellcome Trust, with support from the Economic and Socia

222 Wellcome Trust, Wolfson Foundation, UK Medical Research

223 for Health, Welfare, and Family Affairs, UK Wellcome Trust, Wolfson Foundation, UK Stroke Associatio

224 Wellcome Trust, Wolfson Foundation, UK Stroke Associatio

225 SPARCLE2 was funded by: Wellcome Trust WT086315 A1A (UK and Ireland); Medical Fa

226 s work was made possible by funding from the Wellcome Trust (WT088148MF), the Medical Research Counci